Expedition Therapeutics
Expedition Therapeutics Raises $115M Series B for Oral DPP1 Inhibitor for COPD
Expedition Therapeutics announced $115M in Series B financing on August 5, 2026. Expedition Therapeutics raised an oversubscribed $115 million Series B led by General Atlantic to advance its DPP1 inhibitor EXPD-101 through Phase 2 clinical development in COPD.
Round details
The financing includes backing from General Atlantic, RA Capital, Vivo Capital, Sofinnova Investments, Novo Holdings, Forbion, Sanofi Ventures, Venrock Healthcare Capital Partners. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $115M
How the company plans to use the capital
The company said the financing will support advancement of its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development. It will also be used to expand the company’s pipeline of next-generation therapies for inflammatory diseases and its research discovery work.
Why this matters for GTM teams
According to the release, the Series B was oversubscribed and the first patient has been dosed in a global, randomized Phase 2 clinical trial of EXPD-101 in COPD.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Expedition Therapeutics Series B announcement (Business Wire release, via BioSpace).
Company Info
Investors (8)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


